Complement (Basel, Switzerland)最新文献_第5页

Activation of the alternative pathway of complement by DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (Mergetpa). dl -2-巯基甲基-3-胍基乙基硫代丙酸(Mergetpa)激活补体替代途径。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467885

I von Zabern, R Nolte

引用次数: 0

A sensitive ELISA for the quantitation of human C5a in blood plasma using a monoclonal antibody. 一种利用单克隆抗体定量人血浆中C5a的灵敏ELISA方法。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467875

M Schulze, O Götze

引用次数: 24

Anaphylatoxins: possible roles in disease. 过敏毒素:在疾病中的可能作用。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467894

W Vogt

{"title":"Anaphylatoxins: possible roles in disease.","authors":"W Vogt","doi":"10.1159/000467894","DOIUrl":"https://doi.org/10.1159/000467894","url":null,"abstract":"Anaphylatoxins, in particular C3a and C5a, have various biological activities which suggest a role as mediators of inflammatory reactions: they cause contraction of smooth muscle, histamine release, increase in capillary permeability, adhesion of leukocytes to vascular endothelium, leukocyte chemotaxis, and aggregation of platelets and leukocytes. Most of these effects are supported by the cooperation of other mediators, in particular arachidonic acid derivatives which may be produced by anaphylatoxin-stimulated cells, e.g. leukocytes or endothelium. In vivo effects of the complement peptides depend very much on the site of their generation: intravascular release in the general circulation leads to adverse symptoms such as adult respiratory distress syndrome and shock lung, mainly due to leukocyte activation, aggregation and their accumulation in lung vessels. Intravascular release may be induced by certain drugs, and by contact of blood with the surfaces of bypass or dialysis apparatus. Induction of local inflammatory and defense reactions requires release of anaphylatoxins in tissue spaces. Tissue fluid differs quantitatively from blood plasma in its concentration of complement components. This raises some problems of how efficient concentrations of C3a and C5a can be attained at the site of a lesion to generate a chemotactic gradient capable of attracting blood leukocytes.","PeriodicalId":77697,"journal":{"name":"Complement (Basel, Switzerland)","volume":"3 3","pages":"177-88"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000467894","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14159746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 125

Biochemistry and biology of anaphylatoxins. 过敏毒素的生物化学和生物学。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467889

T E Hugli

{"title":"Biochemistry and biology of anaphylatoxins.","authors":"T E Hugli","doi":"10.1159/000467889","DOIUrl":"https://doi.org/10.1159/000467889","url":null,"abstract":"The molecular architecture of anaphylatoxins has been explored on several levels. Primary, secondary and tertiary structural parameters that dictate function of the C3a, C4a and C5a molecules are being elucidated with the aid of comparative sequence analyses, physical measurements and organic syntheses. Although C3a, C4a and C5a are biologically distinct mediators, as defined by their unique receptor systems, a common genetic origin is apparent from conserved features in their primary structures. Evidence is now available which suggests that similarities in the folding pattern of the anaphylatoxins may dictate a concensus conformation for each factor. We have learned from synthetic peptide studies that the binding (e.g. effector) site in anaphylatoxin molecules exists as a linear sequence contained in the C-terminal portion of the polypeptide. What is also evident is that a preferred conformation is defined for the binding site requiring a proper side chain orientation for optimal bioactivity. It is proposed that folding of the native structure stabilizes this conformation at the binding site. The binding site in C3a contains the essential residues LGLAR folded in an irregular or pseudo-beta-turn and stabilized by an adjacent alpha-helical segment. It is proposed that the alpha-helical segment influences orientation of the side chain residues in the 'binding site'. A similar model is evolving for C5a based on synthetic C5a peptides that express both spasmogenic and chemotactic activities. This helix turn model promises to be representative of an essential structural feature that determines anaphylatoxin activity. We believe that these models contribute significantly to our understanding of the molecular relationships between structure and function for these humoral mediators of inflammation.","PeriodicalId":77697,"journal":{"name":"Complement (Basel, Switzerland)","volume":"3 3","pages":"111-27"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000467889","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14664807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 158

Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody. 单克隆抗体亲和层析纯化人C3b/C4b受体(CR1)的结构和功能研究。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467882

V M Holers, T Seya, E Brown, J J O'Shea, J P Atkinson

{"title":"Structural and functional studies on the human C3b/C4b receptor (CR1) purified by affinity chromatography using a monoclonal antibody.","authors":"V M Holers, T Seya, E Brown, J J O'Shea, J P Atkinson","doi":"10.1159/000467882","DOIUrl":"https://doi.org/10.1159/000467882","url":null,"abstract":"A procedure was devised that has several advantages over previously described methods to purify CR1 from both erythrocytes (E) and the HL-60 promyelocytic cell line. Using a monoclonal antibody immunoaffinity column, CR1 was purified to homogeneity as assessed by silver staining and 2-D gel analysis. Protein purified by this method comigrates on SDS-PAGE with 125I surface-labeled CR1 isolated by immunoprecipitation or iC3-Sepharose affinity chromatograhy and can be specifically immunoblotted with a second monoclonal anti-CR1 antibody. Employing this method, CR1 can be purified to homogeneity in amounts adequate for both functional studies and biochemical microanalysis. Purified E CR1 is functionally active as assessed by its ability to specifically rebind to an iC3-Sepharose affinity column, act as a cofactor for I-mediated cleavage of C3b to C3c and C3d, g and to accelerate decay of both the classical and alternative pathway C3 convertases. Its specific activity is similar to that of CR1 purified by a method not employing the potentially denaturing washing and eluting conditions of immunoaffinity chromatography. The pIs of the two major E CR1 allotypes are both approximately 7.1. Using pooled human E CR1, an amino acid composition was derived which revealed a relatively high proline content. This has also been found in two functionally related and genetically linked complement-regulatory proteins, H and C4-binding protein, NH2-terminal sequencing of E CR1 and HL-60 CR1 was unsuccessful indicating that the NH2-terminus is blocked.","PeriodicalId":77697,"journal":{"name":"Complement (Basel, Switzerland)","volume":"3 2","pages":"63-78"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000467882","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14082031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Suppression of complement-mediated vascular injury at Arthus reaction sites by complement inhibitors. 补体抑制剂抑制补体介导的Arthus反应位点血管损伤。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467876

S S Asghar, K P Dingemans, A Kammeijer, W R Faber, M Y Abdel Mawla

引用次数: 3

Imbalance between polymorphonuclear leukocyte proteases and antiproteases in chronic pyogenic infections and its relation to the proteolysis of complement component C3. 慢性化脓性感染中多形核白细胞蛋白酶与抗蛋白酶失衡及其与补体成分C3蛋白水解的关系。

Complement (Basel, Switzerland) Pub Date : 1986-01-01 DOI: 10.1159/000467874

S Suter

引用次数: 12

Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor. 补体替代途径的位点特异性激活。合成一种由抗体和眼镜蛇毒液因子组成的杂交分子。

Complement (Basel, Switzerland) Pub Date : 1986-01-01

C J Parker, V F White, R J Falk

{"title":"Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.","authors":"C J Parker, V F White, R J Falk","doi":"","DOIUrl":"","url":null,"abstract":"Cobra venom factor (CoF) is an analog of the activated third component of human complement (C3b). Unlike C3b, CoF is completely resistant to inactivation by factors H and I, the endogenous control proteins of the alternative pathway of complement. This property makes CoF a useful reagent when unrestricted activation of complement is desired. CoF was covalently conjugated to the IgG fraction of rabbit antihuman erythrocyte antiserum, and the ability of the hybrid molecules to initiate activation of the alternative pathway at a specific site was tested. The hybrid molecules were heterogeneous polymers (CoFn-IgGn, where n is an integer greater than 1 for at least one of the components), and both components retained their individual functional activities. The alternative-pathway C3/C5 convertase complex was formed by adding purified factors B and D to the hybrid in the presence of magnesium. This complex (antibody-CoFBb) was able to bind to erythrocytes and activate both C3 and C5. Activation of C5 initiated formation of the potentially cytolytic membrane attack complex of complement on the surface of the cell. When used in combination with rabbit serum, the hybrid molecule was a potent mediator of complement-induced hemolysis. The decay kinetics of the hybrid C3/C5 convertase complex when bound to normal human erythrocytes were not first order, but 40% of the activity remained after 3.5 h at 37 degrees C. Conjugation of CoF to specific antibodies will permit investigation of the consequences of alternative-pathway activation at selective sites. These hybrids may also have therapeutic potential.","PeriodicalId":77697,"journal":{"name":"Complement (Basel, Switzerland)","volume":"3 4","pages":"223-35"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14763490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

European Meeting on Complement in Human Disease. September 3-5, 1986, Veszprém (Lake Balaton), Hungary. 人类疾病补体欧洲会议。1986年9月3日至5日，匈牙利veszprachm(巴拉顿湖)。

Complement (Basel, Switzerland) Pub Date : 1986-01-01

引用次数: 0

Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. 血浆C3d、g和终末补体复合物水平评估补体的早期和晚期活化。

Complement (Basel, Switzerland) Pub Date : 1985-01-01 DOI: 10.1159/000467856

T E Mollnes

引用次数: 48